|
1
|
Wesche J, Haglund K and Haugsten EM:
Fibroblast growth factors and their receptors in cancer. Biochem J.
437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parker BC, Engels M, Annala M and Zhang W:
Emergence of FGFR family gene fusions as therapeutic targets in a
wide spectrum of solid tumours. J Pathol. 232:4–15. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Testa U, Castelli G and Pelosi E: Lung
cancers: Molecular characterization, clonal heterogeneity and
evolution, and cancer stem cells. Cancers (Basel). 10:E2482018.
View Article : Google Scholar
|
|
4
|
Meric-Bernstam F, Frampton GM,
Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA,
Ross JS, Miller VA, Su X, et al: Concordance of genomic alterations
between primary and recurrent breast cancer. Mol Cancer Ther.
13:1382–1389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bersani C, Sivars L, Haeggblom L,
DiLorenzo S, Mints M, Ahrlund-Richter A, Tertipis N, Munck-Wikland
E, Näsman A, Ramqvist T and Dalianis T: Targeted sequencing of
tonsillar and base of tongue cancer and human papillomavirus
positive unknown primary of the head and neck reveals prognostic
effects of mutated FGFR3. Oncotarget. 8:35339–35350. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taylor JG VI, Cheuk AT, Tsang PS, Chung
JY, Song YK, Desai K, Yu Y, Chen QR, Shah K, Youngblood V, et al:
Identification of FGFR4-activating mutations in human
rhabdomyosarcomas that promote metastasis in xenotransplanted
models. J Clin Invest. 119:3395–3407. 2009.PubMed/NCBI
|
|
7
|
Lehtinen B, Raita A, Kesseli J, Annala M,
Nordfors K, Yli-Harja O, Zhang W, Visakorpi T, Nykter M, Haapasalo
H and Granberg KJ: Clinical association analysis of ependymomas and
pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression
in aggressive ependymomas. BMC Cancer. 17:3102017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Parker BC, Annala MJ, Cogdell DE, Granberg
KJ, Sun Y, Ji P, Li X, Gumin J, Zheng H, Hu L, et al: The
tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in
glioblastoma. J Clin Invest. 123:855–865. 2013.PubMed/NCBI
|
|
9
|
Agelopoulos K, Richter GH, Schmidt E,
Dirksen U, von Heyking K, Moser B, Klein HU, Kontny U, Dugas M,
Poos K, et al: Deep sequencing in conjunction with expression and
functional analyses reveals activation of FGFR1 in ewing sarcoma.
Clin Cancer Res. 21:4935–4946. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gallia GL, Rand V, Siu IM, Eberhart CG,
James CD, Marie SK, Oba-Shinjo SM, Carlotti CG, Caballero OL,
Simpson AJ, et al: PIK3CA gene mutations in pediatric and adult
glioblastoma multiforme. Mol Cancer Res. 4:709–714. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Grill J, Puget S, Andreiuolo F, Philippe
C, MacConaill L and Kieran MW: Critical oncogenic mutations in
newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr
Blood Cancer. 58:489–491. 2012. View Article : Google Scholar
|
|
12
|
Shukla N, Ameur N, Yilmaz I, Nafa K, Lau
CY, Marchetti A, Borsu L, Barr FG and Ladanyi M: Oncogene mutation
profiling of pediatric solid tumors reveals significant subsets of
embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in
growth signaling pathways. Clin Cancer Res. 18:748–757. 2012.
View Article : Google Scholar :
|
|
13
|
Dam V, Morgan BT, Mazanek P and Hogarty
MD: Mutations in PIK3CA are infrequent in neuroblastoma. BMC
Cancer. 6:1772006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Izycka-Swieszewska E, Brzeskwiniewicz M,
Wozniak A, Drozynska E, Grajkowska W, Perek D, Balcerska A,
Klepacka T and Limon J: EGFR, PIK3CA and PTEN gene status and their
protein product expression in neuroblastic tumours. Folia
Neuropathol. 48:238–245. 2010.
|
|
15
|
Opel D, Poremba C, Simon T, Debatin KM and
Fulda S: Activation of Akt predicts poor outcome in neuroblastoma.
Cancer Res. 67:735–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vaughan L, Clarke PA, Barker K, Chanthery
Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, et
al: Inhibition of mTOR-kinase destabilizes MYCN and is a potential
therapy for MYCN-dependent tumors. Oncotarget. 7:57525–57544. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chesler L, Schlieve C, Goldenberg DD,
Kenney A, Kim G, McMillan A, Matthay KK, Rowitch D and Weiss WA:
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn
protein and blocks malignant progression in neuroblastoma. Cancer
Res. 66:8139–8146. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Segerström L, Baryawno N, Sveinbjörnsson
B, Wickström M, Elfman L, Kogner P and Johnsen JI: Effects of small
molecule inhibitors of PI3K/Akt/mTOR signaling on neuro-blastoma
growth in vitro and in vivo. Int J Cancer. 129:2958–2965. 2011.
View Article : Google Scholar
|
|
19
|
Klempner SJ, Myers AP and Cantley LC: What
a tangled web we weave: Emerging resistance mechanisms to
inhibition of the phosphoinositide 3-kinase pathway. Cancer Discov.
3:1345–1354. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maris JM: Recent advances in
neuroblastoma. N Engl J Med. 362:2202–2211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brodeur GM: Neuroblastoma: Biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Giraud G, Ramqvist T, Pastrana DV, Pavot
V, Lindau C, Kogner P, Orrego A, Buck CB, Allander T, Holm S, et
al: DNA from KI, WU and Merkel cell polyomaviruses is not detected
in childhood central nervous system tumours or neuroblastomas. PLoS
One. 4:e82392009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kocak H, Ackermann S, Hero B, Kahlert Y,
Oberthuer A, Juraeva D, Roels F, Theissen J, Westermann F, Deubzer
H, et al: Hox-C9 activates the intrinsic pathway of apoptosis and
is associated with spontaneous regression in neuroblastoma. Cell
Death Dis. 4:e5862013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Biedler JL, Helson L and Spengler BA:
Morphology and growth, tumorigenicity, and cytogenetics of human
neuroblastoma cells in continuous culture. Cancer Res.
33:2643–2652. 1973.PubMed/NCBI
|
|
25
|
Biedler JL and Spengler BA: A novel
chromosome abnormality in human neuroblastoma and
antifolate-resistant Chines hamster cell lives in culture. J Natl
Cancer Inst. 57:683–695. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sugimoto T, Tatsumi E, Kemshead JT, Helson
L, Green AA and Minowada J: Determination of cell surface membrane
antigens common to both human neuroblastoma and leukemia-lymphoma
cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer
Inst. 73:51–57. 1984.PubMed/NCBI
|
|
27
|
Helson L and Helson C: Human neuroblastoma
cells and 13-cis-retinoic acid. J Neurooncol. 3:39–41.
1985.PubMed/NCBI
|
|
28
|
LaQuaglia MP, Kopp EB, Spengler BA, Meyers
MB and Biedler JL: Multidrug resistance in human neuroblastoma
cells. J Pediatr Surg. 26:1107–1112. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carén H, Kryh H, Nethander M, Sjöberg RM,
Träger C, Nilsson S, Abrahamsson J, Kogner P and Martinsson T:
High-risk neuro-blastoma tumors with 11q-deletion display a poor
prognostic, chromosome instability phenotype with later onset. Proc
Natl Acad Sci USA. 107:4323–4328. 2010. View Article : Google Scholar
|
|
30
|
Kryh H, Carén H, Erichsen J, Sjöberg RM,
Abrahamsson J, Kogner P and Martinsson T: Comprehensive SNP array
study of frequently used neuroblastoma cell lines; copy neutral
loss of heterozygosity is common in the cell lines but uncommon in
primary tumors. BMC Genomics. 12:4432011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Helson C, Zahn Z and Helson L: Reversion
of p-glycoprotein mediated multidrug-resistance to vincristine and
adriamycin by psc-833, a cyclosporine derivative in human
neuroblastoma cell-lines. Int J Oncol. 5:1037–1042. 1994.PubMed/NCBI
|
|
32
|
Bersani C, Haeggblom H, Ursu RG, Giusca
SE, Marklund L, Ramqvist T, Näsman A and Dalianis T: Overexpression
of FGFR3 in HPV-positive tonsillar and base of tongue cancer is
correlated to outcome. Anticancer Res. 38:4683–4690. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Holzhauser S, Kostopoulou ON, Ohmayer A,
Lange BKA, Ramqvist T, Andonova T, Bersani C, Wickström M and
Dalianis T: Antitumor effects in vitro of FGFR and PI3K inhibitors
on human papillomavirus positive and negative tonsillar and base of
tongue cancer. Oncol Lett. In press.
|
|
34
|
Foucquier J and Guedj M: Analysis of drug
combinations: Current methodological landscape. Pharmacol Res
Perspect. 3:e001492015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Patani H, Bunney TD, Thiyagarajan N,
Norman RA, Ogg D, Breed J, Ashford P, Potterton A, Edwards M,
Williams SV, et al: Landscape of activating cancer mutations in
FGFR kinases and their differential responses to inhibitors in
clinical use. Oncotarget. 7:24252–24268. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arenas MA, Del Pino M and Fano V:
FGFR3-related hypochondroplasia: Longitudinal growth in 57 children
with the p. Asn540Lys mutation. J Pediatr Endocrinol Metab.
31:1279–1284. 2018.PubMed/NCBI
|
|
38
|
Chen J, Yang J, Zhao S, Ying H, Li G and
Xu C: Identification of a novel mutation in the FGFR3 gene in a
Chinese family with Hypochondroplasia. Gene. 641:355–360. 2018.
View Article : Google Scholar
|
|
39
|
Wang L, Šuštić T, Leite de Oliveira R,
Lieftink C, Halonen P, van de Ven M, Beijersbergen RL, van den
Heuvel MM, Bernards R and van der Heijden MS: A functional genetic
screen identifies the phosphinositide 3-kinase pathway as a
determinant of resistance to fibroblast grown factor receptor
inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol.
71:858–862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Mikse O, Liao RG, Li Y, Tan L,
Janne PA, Gray NS, Wong KK and Hammerman PS: Ligand-associated
ERBB2/3 activation confers acquired resistance to FGFR inhibition
in FGFR3-dependent cancer cells. Oncogene. 34:2167–2177. 2015.
View Article : Google Scholar
|
|
41
|
Herrera-Abreu MT, Pearson A, Campbell J,
Shnyder SD, Knowles MA, Ashworth A and Turner NC: Parallel RNA
interference screens identify EGFR activation as an escape
mechanism in FGFR3-mutant cancer. Cancer Discov. 3:1058–1071. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brands RC, Knierim LM, De Donno F,
Steinacker V, Hartmann S, Seher A, Kübler AC and Müller-Richter
UDA: Targeting VEGFR and FGFR in head and neck squamous cell
carcinoma in vitro. Oncol Rep. 38:1877–1885. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Singleton KR, Hinz TK, Kleczko EK, Marek
LA, Kwak J, Harp T, Kim J, Tan AC and Heasley LE: Kinome RNAi
screens reveal synergistic targeting of MTOR and FGFR1 pathways for
treatment of lung cancer and HNSCC. Cancer Res. 75:4398–4406. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cai W, Song B and Ai H: Combined
inhibition of FGFR and mTOR pathways is effective in suppressing
ovarian cancer. Am J Transl Res. 11:1616–1625. 2019.PubMed/NCBI
|
|
45
|
Munster P, Aggarwal R, Hong D, Schellens
JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC,
Bergsland E, et al: First-in-human phase I study of GSK2126458, an
oral pan-class I phosphatidylinositol-3-kinase inhibitor, in
patients with advanced solid tumor malignancies. Clin Cancer Res.
22:1932–1939. 2016. View Article : Google Scholar
|
|
46
|
Tamura R, Yoshihara K, Saito T, Ishimura
R, Martínez-Ledesma JE, Xin H, Ishiguro T, Mori Y, Yamawaki K, Suda
K, et al: Novel therapeutic strategy for cervical cancer harboring
FGFR3-TACC3 fusions. Oncogenesis. 7:42018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zheng X, Naiditch J, Czurylo M, Jie C,
Lautz T, Clark S, Jafari N, Qiu Y, Chu F and Madonna MB:
Differential effect of long-term drug selection with doxorubicin
and vorinostat on neuroblastoma cells with cancer stem cell
characteristics. Cell Death Dis. 4:e7402013. View Article : Google Scholar : PubMed/NCBI
|
